Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2026. The document serves as a transaction notification regarding a specific insider trade rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific transaction:
- Instrument: American Depositary Shares (ADS)
- Transaction Price: $59.5200 per ADS
- Transaction Volume: 70.566 ADS
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of notional ADS by an executive within a supplemental savings plan account following the reinvestment of dividends.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine regulatory disclosure of an executive transaction.
Important Facts for Investors
- Executive Action: Maya Martinez-Davis, President of GSK US, acquired 70.566 ADS.
- Transaction Nature: The acquisition was automatic via dividend reinvestment in the GSK Executive Supplemental Savings Plan, not a direct open-market purchase.
- Transaction Date: February 20, 2026.
- Market Data: The transaction occurred on the New York Stock Exchange (XNYS) at a price of $59.52.